Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL
Recalled by Imprimis NJOF, LLC
Drug recall
Imprimis NJOF, LLC
Class II — moderate
Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Imprimis NJOF, LLC has recalled Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on January 14, 2026 and was initiated on December 18, 2025. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, with approximately 314 boxes of 6,280 pre-filled syringes affected. The company behind the recall is Imprimis NJOF, LLC, based in Ledgewood, NJ. The FDA describes the product as: “Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.”
Why was Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL recalled?
According to the FDA, the stated reason for the recall is: “Presence of particulate matter - Glass like particles.” In plain terms, this recall relates to foreign material.
A foreign material recall means that pieces of something which should not be in food — such as metal, plastic, or glass — may be present. These can pose a choking hazard or cause injury. Recalls like these are issued to remove the affected product before anyone is hurt.
What should you do?
If you think you may have bought Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, compare it against the product description and identifying codes (Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Imprimis NJOF, LLC or your local health authority.
About this recall
This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Full recall details
- Status
- Ongoing
- Date reported
- January 14, 2026
- Recall started
- December 18, 2025
- Distributed in
- NJ
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL recalled?+
According to the FDA: Presence of particulate matter - Glass like particles.
How serious is this recall?+
Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
What should I do if I have Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0251-2026. Information last synced from the FDA on July 6, 2026.